Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing

Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed in research settings, and is moving toward clinical settings with the development of ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketchum, Fred B., Chin, Nathaniel A., Grill, Joshua, Gleason, Carey E., Erickson, Claire, Clark, Lindsay R., Paulsen, Jane S., Kind, Amy J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402800/
https://www.ncbi.nlm.nih.gov/pubmed/35213786
http://dx.doi.org/10.1002/alz.12620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402800/
https://www.ncbi.nlm.nih.gov/pubmed/35213786
http://dx.doi.org/10.1002/alz.12620

Ejemplares similares